DrugPatentWatch Database Preview
Desipramine hydrochloride - Generic Drug Details
What are the generic sources for desipramine hydrochloride and what is the scope of patent protection?
Desipramine hydrochloride
is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Amneal Pharms Co, Ani Pharms Inc, Heritage Pharms Inc, Novast Labs, Sandoz, Usl Pharma, and Us Pharm Holdings, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for desipramine hydrochloride. Nine suppliers are listed for this compound.
Summary for desipramine hydrochloride
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 9 |
| NDAs: | 22 |
| Drug Master File Entries: | 9 |
| Suppliers / Packagers: | 9 |
| Bulk Api Vendors: | 54 |
| Clinical Trials: | 60 |
| Patent Applications: | 1,935 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for desipramine hydrochloride |
| DailyMed Link: | desipramine hydrochloride at DailyMed |
Recent Clinical Trials for desipramine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke University | Phase 4 |
| Stanford University | Phase 4 |
| State University of New York at Buffalo | Phase 4 |
Recent Litigation for desipramine hydrochloride
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. | 2017-07-06 |
Pharmacology for desipramine hydrochloride
| Drug Class | Tricyclic Antidepressant |
Medical Subject Heading (MeSH) Categories for desipramine hydrochloride
Synonyms for desipramine hydrochloride
| 10-11-Dihydro-N-methyl-5H-dibenz(Z)[b,f]azepine-5-propanamine hydrochloride |
| 10,11-Dihydro-5-(3-(methylamino)prop-yl)-5h-dibenz(b,f)azepine hydro-chloride |
| 10,11-Dihydro-5-(3-(methylamino)propyl)-5H-dibenz(b,f)azepine hydrochloride |
| 10,11-Dihydro-5-(3-(methylamino)propyl)-5H-dibenz(b,f)azepine monohydrochloride |
| 10,11-Dihydro-N-methyl-5H-dibenz-[b,f]azepine hydrochloride |
| 10,f]azepine hydrochloride |
| 10,f]azepine monohydrochloride |
| 1Y58DO4MY1 |
| 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine hydrochloride |
| 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine hydrochloride |
| 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine hydrochloride |
| 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;hydrochloride |
| 5-(3-Methylaminopropyl)-5H-dibenz[b,f]azepine hydrochloride |
| 50-47-5 (Parent) |
| 58-28-6 |
| 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride |
| 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, hydrochloride |
| 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, monohydrochloride |
| 5H-Dibenz[b, 10,11-dihydro-5-[3-(methylamino)propyl]-, hydrochloride |
| 5H-Dibenz[b, 10,11-dihydro-5-[3-(methylamino)propyl]-, monohydrochloride |
| 5H-Dibenz[b, 10,11-dihydro-N-methyl-, monohydrochloride |
| AC1L2324 |
| AKOS015994722 |
| AN-083 |
| B7261 |
| BG0162 |
| CAS-58-28-6 |
| CC-26348 |
| CCG-38909 |
| CHEBI:4449 |
| CHEMBL1696 |
| CPD000036827 |
| CS-8201 |
| CTK8F9062 |
| D 3900 |
| D00812 |
| Demethylimipramine hydrochloride |
| Desimipramine hydrochloride |
| Desimipramine, hydrochloride |
| Desipramine Hcl |
| Desipramine hydrochloride (JAN/USP) |
| Desipramine hydrochloride [USAN:JAN] |
| Desipramine hydrochloride [USAN:USP:JAN] |
| Desipramine Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material |
| Desipramine hydrochloride solution, drug standard, 1.0 mg/mL in methanol |
| Desipramine hydrochloride, >=98% (TLC), powder |
| Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Desipramine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material |
| Desipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Desipramine monohydrochloride |
| Desiprimine |
| Desmethylimipramine chloride |
| Desmethylimipramine hydrochloride |
| Desmethylimipramine monohydrochloride |
| Desmethylimipramine-hydrochloride |
| Despiramine hydrochloride |
| DMI hydrochloride |
| DSSTox_CID_26942 |
| DSSTox_GSID_46942 |
| DSSTox_RID_82024 |
| DTXSID9046942 |
| EINECS 200-373-1 |
| Epitope ID:224551 |
| EU-0100358 |
| EX 4355 |
| EX-4355 |
| FT-0603109 |
| G 35020 |
| G-35020 |
| GMI |
| HMS1569E07 |
| HMS1920C22 |
| HY-B1272 |
| Imipraminedemethyl hydrochloride |
| iren |
| JB 8181 |
| JB-8181 |
| KS-1296 |
| LP00358 |
| LS-60422 |
| MFCD00058108 |
| MLS000028418 |
| MLS000038088 |
| MLS001056757 |
| MLS002222246 |
| MLS002548871 |
| MolPort-000-917-727 |
| N-(.gamma.-Methylaminopropyl)iminodibenzyl hydrochloride |
| N-(gamma-Methylaminopropyl)iminodibenzyl hydrochloride |
| NC00681 |
| NCGC00015340-02 |
| NCGC00015340-14 |
| NCGC00093794-01 |
| NCGC00093794-02 |
| NCGC00093794-03 |
| NCGC00093794-04 |
| NCGC00093794-05 |
| NCGC00261043-01 |
| Norpolake |
| Norpramin |
| Norpramin (TN) |
| Nortimil |
| NSC 114901 |
| NSC-114901 |
| NSC-756719 |
| NSC114901 |
| NSC756719 |
| Opera_ID_943 |
| Pertofran |
| Pertofrane |
| Pertofrin |
| Pertrofan |
| Petylyl |
| Pharmakon1600-01500227 |
| Prestwick_706 |
| REGID_for_CID_65327 |
| RMI 9,384A |
| RMI-9384A |
| SAM002264605 |
| SC-57976 |
| SCHEMBL41992 |
| SMR000036827 |
| SPECTRUM1500227 |
| SR-01000003060 |
| SR-01000003060-2 |
| SR-01000003060-8 |
| Tox21_110129 |
| Tox21_110129_1 |
| Tox21_500358 |
| UNII-1Y58DO4MY1 |
| VA10690 |
| WLN: T C676 BN&T&J B3M1 &GH |
| XAEWZDYWZHIUCT-UHFFFAOYSA-N |
US Patents and Regulatory Information for desipramine hydrochloride
Expired US Patents for desipramine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Us Pharm Holdings | NORPRAMIN | desipramine hydrochloride | TABLET;ORAL | 014399-005 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Sanofi Aventis Us | PERTOFRANE | desipramine hydrochloride | CAPSULE;ORAL | 013621-001 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Sanofi Aventis Us | PERTOFRANE | desipramine hydrochloride | CAPSULE;ORAL | 013621-002 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Us Pharm Holdings | NORPRAMIN | desipramine hydrochloride | TABLET;ORAL | 014399-003 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Us Pharm Holdings | NORPRAMIN | desipramine hydrochloride | TABLET;ORAL | 014399-005 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Us Pharm Holdings | NORPRAMIN | desipramine hydrochloride | TABLET;ORAL | 014399-007 | Feb 11, 1982 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
